Mi­rati and MD An­der­son team up on KRAS; Sanofi inks deal with a Har­vard spin­out for oral bi­o­log­ics

Mi­rati, the oth­er KRAS-fo­cused biotech, is get­ting some ex­tra am­mo as it looks to leapfrog Am­gen in the hunt for the first, most ef­fec­tive and most broad­ly ef­fec­tive for one of the most ubiq­ui­tous and hard-to-hit onco­genes.

The Cal­i­for­nia biotech has signed a re­search and de­vel­op­men­tal with MD An­der­son to help ad­vance both Mi­rati’s lead KRAS G12C mol­e­cule — the one that’s now proven ef­fec­tive in cer­tain lung can­cer pa­tients — and a pre­clin­i­cal mol­e­cule that goes af­ter an­oth­er KRAS mu­ta­tion, G12D. The Texas-based re­search in­sti­tute will help Mi­rati de­sign and run pre­clin­i­cal and clin­i­cal stud­ies for sev­er­al sol­id tu­mors, in­clud­ing non-small cell lung, pan­cre­at­ic, col­orec­tal and gy­ne­co­log­i­cal can­cers, over the next 5 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER